First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRAS G12C Cancers FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRAS G12C FMC-376 has the potential to transform patient outcomes with its abi lity to overcome both innate and acquired resistance mechanisms and brain metastases BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation , a precision... Read More

6 out of 7 eligible patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) responded to treatment (ORR of 86%) and all responding patients achieved complete response (CR) No grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in any of the eligible patients Initial data suggest the potential of our decentralized manufacturing and supply... Read More